Kansas
Cancer biologic therapy trials in Kansas
37 cancer biologic therapy studies are recruiting participants at sites in 27 cities across Kansas as of November 18, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every Kansas city with a recruiting study
By research area: Lymphoma (14), Lung Cancer (13), Breast Cancer (7), Melanoma (2), Prostate Cancer (1).
Westwood (24), Kansas City (19), Olathe (17), Overland Park (16), Salina (15), Lawrence (14), Topeka (14), Hays (13), Wichita (11), Fairway (8), Pratt (4), Chanute (3), Dodge City (3), El Dorado (3), Independence (3), Kingman (3), Liberal (3), Newton (3), Parsons (3), Pittsburg (3), Wellington (3), Winfield (3), Garden City (2), Great Bend (2), McPherson (2), Leawood (1), Manhattan (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Breast cancer: recently updated in Kansas
Basic details from each study's public record (the 12 most recently updated of 37). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Hays · Kansas City · Lawrence · and 5 more U.S. locations
- Registry record
- NCT06058377 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Kansas on ClinicalTrials.gov.
Lung cancer: recently updated in Kansas
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Hays · Lawrence · Olathe · and 2 more U.S. locations
- Registry record
- NCT06498635 · updated
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Fairway · Kansas City · Olathe · and 2 more U.S. locations
- Registry record
- NCT07388524 · updated
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Fairway · Kansas City · Overland Park · and 1 more U.S. location
- Registry record
- NCT06287775 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Olathe · Pratt · Wichita
- Registry record
- NCT04267848 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Wichita
- Registry record
- NCT04181060 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Kansas on ClinicalTrials.gov.
Prostate cancer: recently updated in Kansas
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Hays · Lawrence · Olathe · and 4 more U.S. locations
- Registry record
- NCT03866382 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Kansas on ClinicalTrials.gov.
Lymphoma: recently updated in Kansas
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Kansas City · Westwood
- Registry record
- NCT03739814 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Hays · Kansas City · Lawrence · and 5 more U.S. locations
- Registry record
- NCT06337318 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Hays · Kansas City · Lawrence · and 5 more U.S. locations
- Registry record
- NCT04269902 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Wichita
- Registry record
- NCT05675410 · updated
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- PeproMene Bio, Inc.
- Recruiting in
- Kansas City
- Registry record
- NCT05370430 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Kansas on ClinicalTrials.gov.
Ask about studies in Kansas
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections